https://d-luciferininhibitor.c....om/tsunami-generated
Where available, pre-CRT samples had been tested for PD-L1 appearance (immunohistochemistry) and scored at pre-specified (25%) and post-hoc (1%) TC cutoffs. Treatment-effect HRs were estimated from unstratified-Cox-proportional-hazards models (Kaplan-Meier-estimated medians). RESULTS 709/713 randomised patients obtained durvalumab (n=473) or placebo (n=236). 451 (63%) were PD-L1-evaluable 35%, 65%, 67%, 33%, and 32% had TC ≥25%, less then 25%, ≥1%, less then 1%, and 1-24%, respectively. As o
إعجاب
علق
شارك
